ABBV-744 as a potential therapeutic option for aggressive cancers Secrets
In Section C, participants will acquire ABBV-744 and oral navitoclax. In Segment D, members will acquire ABBV-744 and ruxolitinib. Individuals will get treatment until sickness progression or even the contributors are unable to tolerate the study drugs.Ubiquitin-linked proteins that regulate The steadiness of important super enhancer-mediated prote